Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
18h
The Montgomery Advertiser on MSNAlabama still fighting HIV: 'In the South is where we have the majority of the problems':Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
1don MSN
A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...
1d
Clinical Trials Arena on MSNMSD to push for approval of HIV combo after Phase III successMSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
HIV is currently the only disease carrying a felony charge if someone knowingly transmits it to another person. The Senate ...
A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results